Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Feb 8;17(1):60.
doi: 10.1186/s12888-017-1230-5.

Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools

Chad A Bousman  1   2   3   4 , Malcolm Forbes  5 , Mahesh Jayaram  5 , Harris Eyre  5   6   7 , Charles F Reynolds  8 , Michael Berk  5   9   6 , Malcolm Hopwood  5 , Chee Ng  5
Affiliations
Review

Antidepressant prescribing in the precision medicine era: a prescriber's primer on pharmacogenetic tools

Chad A Bousman et al. BMC Psychiatry. .

Abstract

About half of people who take antidepressants do not respond and many experience adverse effects. These detrimental outcomes are in part a result of the impact of an individual's genetic profile on pharmacokinetics and pharmcodynamics. If known and made available to clinicians, this could improve decision-making and antidepressant therapy outcomes. This has spurred the development of numerous pharmacogenetic-based decision support tools. In this article, we provide an overview of pharmacogenetic decision support tools, with particular focus on tools relevant to antidepressants. We briefly describe the evolution and current state of antidepressant pharmacogenetic decision support tools in clinical practice, followed by the evidence-base for their use. Finally, we present a series of considerations for clinicians contemplating use of these tools and discuss the future of antidepressant pharmacogenetic decision support tools.

Keywords: Decision support; Major depressive disorder; Pharmacogenomics; Precision medicine; Psychiatry.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overview of current and future development of pharmacogenetic-based decision support tools. *These factors are typically included in decision algorithms of currently available pharmacogenetic-based decision support tools
Fig. 2
Fig. 2
Number of pharmacogenetic-based decision support tools available by country/region
See this image and copyright information in PMC

References

    1. Pharmaceutical market [http://dx.doi.org/10.1787/data-00545-en]
    1. Papakostas GI. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J Clin Psychiatry. 2009;70(Suppl 6):16–25. doi: 10.4088/JCP.8133su1c.03. - DOI - PubMed
    1. Papakostas GI. Tolerability of modern antidepressants. J Clin Psychiatry. 2008;69(Suppl E1):8–13. - PubMed
    1. Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):126–35. doi: 10.1177/070674371005500303. - DOI - PubMed
    1. Berk M, Berk L. Is ‘depression’ the new ‘neurosis’? Aust N Z J Psychiatry. 2013;47(4):297–8. doi: 10.1177/0004867413482495. - DOI - PubMed

MeSH terms